98%
921
2 minutes
20
Neurodegenerative diseases (NDs) are disorders that drastically alter the physiological functioning of neurons in the brain. These processes are often accompanied by abnormal protein aggregates that alter the physical and chemical properties of brain tissue and peripheral nerves. The causes of NDs are complex, involving genetic factors, neuroinflammation, oxidative stress, environmental influences, and lifestyle, while symptoms and progression vary significantly based on the mechanisms of cell death. Currently, no definitive treatment exists for NDs, as the underlying degenerative processes remain poorly understood. Existing therapies focus on symptom alleviation but are insufficient to halt or prevent disease progression. This highlights the urgent need for strategies that mimic the pathophysiology of NDs, facilitating deeper insights and the development of effective treatments. Conventional in vitro and in vivo models attempt to replicate NDs but often fail to capture the physiological complexity of nervous tissue and its interactions. In this context, 3D microfluidic bioprinting emerges as a transformative technology. By enabling precise deposition of cells and biomaterials, it allows the creation of in vitro models with a high degree of structural and functional complexity. These advancements provide a valuable platform for faithfully modeling NDs, bridging critical gaps in our understanding, and paving the way toward innovative therapeutic approaches.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177659 | PMC |
http://dx.doi.org/10.1002/ibra.12196 | DOI Listing |
Neurochem Res
September 2025
Biology and Health Laboratory, Faculty of Sciences, Ibn Tofail University, Kenitra, Morocco.
Parkinson's disease (PD) is characterized by impairments in motor control following the degeneration of dopamine-producing neurons located in the substantia nigra pars compacta. Environmental pesticides such as Paraquat (PQ) and Maneb (MB) contribute to the onset of PD by inducing oxidative stress (OS). This study evaluated the therapeutic efficacy of moderate physical activity (PA) on both motor and non-motor symptoms in a Wistar rat model of Paraquat and Maneb (PQ/MB) induced PD.
View Article and Find Full Text PDFJ Magn Reson Imaging
September 2025
Neuroimaging Laboratory, School of Medicine, University of Navarra, Pamplona, Spain.
Mol Biol Rep
September 2025
School of Pharmacy, Heilongjiang University of Chinese Medicine, NO 24 Heping Road, 150040, Harbin, P. R. China.
Lysosome-dependent cell death (LDCD) is a regulated form of cell death initiated by increased lysosomal membrane permeability, leading to the cytoplasmic release of lysosomal enzymes and subsequent cellular damage. Molecular mechanisms controlling LDCD include lysosomal membrane instability and lysosomal enzyme release, which together lead to cell damage. A more profound comprehension of these underlying mechanisms may reveal new therapeutic targets for diseases associated with lysosomal dysfunction.
View Article and Find Full Text PDFInflammopharmacology
September 2025
Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India.
The NOD‑like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a key molecular complex that amplifies inflammatory cascades by maturing interleukin‑1 beta (IL-1β) and interleukin‑18 (IL-18) and inducing pyroptosis. It serves as a major driver and co-driver of numerous diseases associated with chronic inflammation. Dysregulated NLRP3 activation contributes to the progression of disorders such as rheumatoid arthritis, inflammatory bowel disease, neurodegenerative diseases and atherosclerosis.
View Article and Find Full Text PDFMol Biol Rep
September 2025
Phytoveda Pvt. Ltd, Mumbai, 400022, India.
Background: The dysregulation of long-chain noncoding RNAs (lncRNAs) causes several complex human diseases including neurodegenerative disorders across the globe.
Methods And Results: This study aimed to investigate lncRNA expression profiles of Withania somnifera (WS)-treated human neuroblastoma SK-N-SH cells at different timepoints (3 & 9 h) and concentrations (50 & 100 µg/mL) using RNA sequencing. Differential gene expression analysis showed a total of 4772 differentially expressed lncRNAs, out of which 3971 were upregulated and 801 were downregulated compared to controls.